Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M105446200 on September 10, 2001

J. Biol. Chem., Vol. 276, Issue 47, 44315-44322, November 23, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/47/44315    most recent
M105446200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Otipoby, K. L.
Right arrow Articles by Clark, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Otipoby, K. L.
Right arrow Articles by Clark, E. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

CD22 Regulates B Cell Receptor-mediated Signals via Two Domains That Independently Recruit Grb2 and SHP-1*

Kevin L. OtipobyDagger §, Kevin E. Draves, and Edward A. ClarkDagger

From the Departments of Dagger  Immunology and  Microbiology, University of Washington, Seattle, Washington 98195

Received for publication, June 12, 2001, and in revised form, July 19, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Recognition of antigen by the B cell antigen receptor (BCR) determines the subsequent fate of a B cell and is regulated in part by the involvement of other surface molecules, termed coreceptors. CD22 is a B cell-restricted coreceptor that gets rapidly tyrosyl-phosphorylated and recruits various signaling molecules to the membrane following BCR ligation. Although CD22 contains three immunoreceptor tyrosine-based inhibitory motifs (ITIMs), only the two carboxyl-terminal ITIM tyrosines are required for efficient recruitment of the SHP-1 phosphatase after BCR ligation. Furthermore, Grb2 is inducibly recruited to CD22 in human and murine B cells. Unlike SHP-1, Grb2 recruitment to CD22 is not inhibited by specific doses of the Src family kinase-specific inhibitor PP1. The tyrosine residue in CD22 required for Grb2 recruitment (Tyr-828) is distinct and independent from the two ITIM tyrosines required for efficient SHP-1 recruitment (Tyr-843 and Tyr-863). Individually both Lyn and Syk are required for maximal phosphorylation of CD22 following ligation of the BCR, and together Lyn and Syk are required for all of the constitutive and induced tyrosine phosphorylation of CD22. We propose that the cytoplasmic tail of CD22 contains two domains that regulate signal transduction pathways initiated by the BCR and B cell fate.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The binding of antigenic determinants by the BCR1 on B cells is the initiating event in antigen-specific B cell responses. The generation of a productive humoral response is only one of many possible outcomes; engagement of the BCR complex by antigen can induce survival, proliferation, apoptosis, clonal nonresponsiveness (anergy), or differentiation into memory B cells or plasma cells (1). Not surprisingly, many factors determine which fate a B cell will choose, including the developmental stage of the B cell, the amount and form of the antigen, the microanatomical location of the B cell, and the availability of accessory cells. Somehow these factors in the extracellular milieu contribute to and alter the intracellular signal transduction pathways initiated by the BCR complex, resulting in differential gene expression and altered B cell fate. Recently the involvement of additional molecules expressed on the surface of B cells in delivering these extracellular cues and regulating the quality and/or quantity of BCR-initiated signals has become evident (2-6). These coreceptors, which include CD22, CD19, CD21, Fcgamma RIIb, and CD72, regulate many signal transduction pathways in both "positive" and "negative" manners, thereby facilitating a range of B cell responses (2).

Unlike receptor tyrosine kinases, the BCR has no intrinsic kinase. Engagement of the BCR rapidly recruits and activates protein tyrosine kinases (PTKs), which initiate perhaps all of the downstream biochemical events after antigen receptor stimulation (2, 7). Three major families of PTKs are expressed in B cells: Lyn, Blk, Fyn, Lck, and Fgr of the Src family; Syk of the Syk/Zap70 family; and Btk of the Tec family (2, 7). Activation of these kinases leads to tyrosine phosphorylation of various substrates, including coreceptors, adaptor molecules, and other enzymes (8). The phosphorylation of coreceptors produces potential binding sites for downstream signaling molecules and promotes the formation of signaling complexes at the lipid bilayer juxtaposed to potential substrates.

CD22 is a B cell-restricted type I surface glycoprotein (3, 9, 10). The extracellular portion of CD22 contains seven immunoglobulin (Ig)-like domains. The two amino-terminal Ig-like domains are capable of binding ligands with alpha 2right-arrow6-linked sialic acid moieties expressed on epithelial, endothelial, B, and T cells (3). However, the specific ligands recognized by CD22 in vivo are not yet well defined (3). The cytoplasmic tail of CD22 contains six conserved tyrosine residues, some or all of which are rapidly phosphorylated upon engagement of the BCR (11-14). Phosphorylation of CD22 provides binding sites for many Src homology 2-containing molecules, including Lyn and Syk (15, 16), the protein tyrosine phosphatase SHP-1 (16-19), phospholipase Cgamma -1 (16), and phosphoinositide 3-kinase (15). Furthermore, CD22 can physically associate with the BCR complex (20, 21). By recruiting various signaling molecules to the BCR complex, CD22 may regulate BCR-mediated signal transduction pathways and B cell function.

This hypothesis is supported by evidence from studies of CD22-deficient mice. Although cd22-/- mice develop relatively normal numbers of peripheral B cells, cd22-/- B cells have an abnormal surface phenotype: they have decreased expression of surface IgM (sIgM) and elevated expression of major histocompatibility complex class II molecules, indicative of B cells that have encountered antigen in vivo (22-25). In agreement with a so-called "hyper-responsive" phenotype, engagement of the BCR on cd22-/- B cells leads to greater increases in levels of intracellular free calcium ([Ca2+]i) compared with wild-type B cells (22-25). Based on these data it has been proposed that CD22 functions primarily as a negative regulator of BCR signal transduction (18, 26). However, B cells from CD22-deficient mice proliferate less well compared with wild-type B cells when treated with the same reagent that leads to augmented release of [Ca2+]i (22, 24). Furthermore, cd22-/- mice generate decreased antibody responses when immunized with a thymus-independent type II antigen (22, 25). These data suggest that CD22 can also function as a positive regulator of BCR-mediated signals. How CD22 might regulate B cell responses in both a positive and a negative manner has remained an enigma. We have looked at the role that single tyrosine residues play in the recruitment of signaling proteins and the role that CD22 plays in activating mitogen-activated protein kinase (MAPK) pathways. Here we present data suggesting that the cytoplasmic tail of CD22 contains two signaling domains that regulate signal transduction pathways initiated by the BCR. These findings may explain the paradoxical phenotype of CD22-deficient mice.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mice-- cd22+/- mice, which had been backcrossed to C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME) greater than seven generations, were crossed to generate cd22+/+ and cd22-/- mice (22). Litter- and gender-matched, 7-12-week-old cd22+/+ and cd22-/- mice were used for all of the mouse studies. All mice were raised in the specific pathogen-free facility at the University of Washington. Mice were genotyped for the wild-type and mutant alleles of cd22 by subjecting tail DNA to three PCRs. Briefly, one forward primer that annealed in intron 2 (27) (5'-GCC ACG CTG GCC TCA GAC TCA TAG CAA TTC-3') was used in three separate reactions with different reverse primers that annealed in intron 3 (5'-TCT CCA GAC CCA GCT ACC AGC CTG GGC CTC-3'), intron 4 (5'-GGT CCC TCT TTC GTG CCG CTA GAA CAG TTG-3'), or the neomycin cassette (5'-GGC CGG CTG GGT GTG GCG GAC CGC TAT CAG-3'). The PCRs generated a 207-base pair fragment from the wild-type allele with primers that annealed in intron 2/intron 3, a 342-base pair fragment from the mutant allele with primers that annealed in intron 2/neomycin, and 829- and 1309-base pair fragments from wild-type and mutant alleles, respectively, with primers that annealed in intron 2/intron 4.

Cells-- The EBV- Burkitt's lymphoma line BJAB was obtained from ATCC and cultured in RP10 (RPMI 1640 medium (Fisher Scientific) supplemented with 10% fetal calf serum (BioWhittaker, Walkersville, MD), 1 mM sodium pyruvate, and 1× nonessential amino acids (Irvine Scientific, Santa Ana, CA), 2 mM L-glutamine (Gemini Bioproducts, Woodland, CA), and 100 units of penicillin-streptomycin (Life Technologies, Inc.)). Wild-type, Lyn-, Syk-, and Lyn-Syk- chicken DT40 cells (28, 29) were cultured in RP10 with 1% chicken serum (Life Technologies, Inc.) and 50 µM 2-mercaptoethanol.

Reagents-- Purified mouse B cells were prepared as described previously (22). mAbs to murine CD22 (2D6), human CD22 (HD39), c-Myc (9E10), and phosphotyrosine (4G10) and the myeloma protein mouse IgG1 (MOPC21) were prepared from mouse ascites (14, 16). mAb to chicken IgM (M4) and control mouse IgM (FC-1) were purified over protein A-Sepharose columns from ammonium sulfate-precipitated culture supernatants (28). In some experiments, mAbs were conjugated to biotin as described previously (30). Rabbit antiserum to JNK1 (C-17) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Blotting antisera to phospho-ERK and phospho-JNK were purchased from Promega (Madison, WI), while the phospho-p38 MAPK antiserum was purchased from New England Biolabs (Beverly, MA). mAb to Grb2 was purchased from Pharmingen/Transduction Laboratories (San Diego, CA). Goat F(ab')2 anti-mouse IgM serum, goat F(ab')2 anti-human IgM serum, goat F(ab')2 IgG, and rat IgG were purchased from Jackson ImmunoResearch (West Grove, PA), and PP1 was purchased from BioMol Research Laboratories (Plymouth Meeting, PA).

CD22 Expression Constructs for Human and Chicken Cells-- Six mutant constructs that contained single tyrosine to phenylalanine mutations were generated from pcDNAmCD22-HA (16), a full-length cDNA of murine cd22 in pcDNA-3 with a 3' EcoRI site, HA tag, stop codon, and XhoI site replacing the natural stop codon. Forward primers with the indicated mutation (Y773F, 5'-CAG GGA TGC TTC AAT CCG GCA-3'; Y783F, 5'-ACT GTT AGT TTT GCC ATC TTG-3'; Y817F, 5'-ACG GTC ACT TTC TCG GTG ATA-3'; Y828F, 5'-ATG GGG GAT TTT GAG AAT GTG-3'; Y843F, 5'-AGC ATC CAT TTC TCA GAG CTG-3'; and Y863F, 5'-GAC GTA GAC TTT GTG ACC CTC-3') were used with the commercially available Sp6 reverse primer to generate six mutant fragments by PCR mutagenesis. After purifying the PCR products corresponding to the six mutated 3'-regions of cd22, another set of PCRs with pcDNAmCD22-HA as the template was set up using the mutated fragments, a forward primer that bound the 5'-end of pcDNAmCD22-HA (5'-GAT CGG ATC CGC GGC CTG GGA GAG AAA TAG CAG-3'), and the Sp6 reverse primer. Amplified full-length, HA-tagged wild-type or mutant murine cd22 cDNA products were then ligated into pcDNA3 after digesting both the PCR fragments and the vector with BamHI and XhoI. Since the HA tag encodes three tyrosine residues, it was removed and replaced with a c-myc tag and stop codon in each of the wild type and six mutants by setting up seven triple-ligation reactions, each containing the purified, untagged insert from BamHI- and EcoRI-digested wild-type or mutant HA-tagged cd22, EcoRI- and XhoI-digested c-myc tag/stop codon (generated by annealing 5'-TCG AGT TAC AAC AAG TCC TCT TCA GAA ATG AGC TTT TGC TCC TCT GCG-3' and 5'-AAT TCG CAG AGG AGC AAA AGC TCA TTT CTG AAG AGG ACT TGT TGT AAC-3'), and BamHI- and XhoI-digested pcDNA3. Constructs were verified by restriction and sequence analysis. For cloning into the chicken expression vector pApuro-2 (28), the full-length murine cd22 cDNA with SalI sites at 5'- and 3'-ends and an in-frame c-myc tag and stop codon just upstream of the 3' SalI site was generated by PCR amplification from pmCD22-4 (14) using appropriate primers (5'-GAT GAA TTC TCC CAC CCA GAC GAG ACA CCA TGC GCG TCC ATT ACC TGT GGC T-3' and 5'-ACG CGT CGA CTC ACA GAT CCT CTT CTG AGA TGA GTT TTT GTT CCT CGA GGT GCT TGA GGG TCA CAT AGT-3'). After digesting the PCR fragment with SalI, it was cloned into SalI-digested pApuro-2. The pApuro-2-mCD22 construct was verified by restriction and sequence analysis.

Transfections-- BJAB B cells in exponential phase were washed twice in electroporation medium (RPMI 1640 medium supplemented with 15% fetal calf serum, 1 mM sodium pyruvate, 1× nonessential amino acids, and 2 mM L-glutamine) and resuspended at 3 × 107 ml-1. Next, 350 µl of the cell suspension was placed in a 0.4-cm cuvette with 50 µg of linearized plasmid DNA containing c-myc-tagged wild-type or mutant cd22 inserts in pcDNA-3 for 10 min on ice. Cells were then electroporated (Bio-Rad Gene Pulser with Capacitance Extender) at 230 V and 960 microfarads. After electroporation, cells were placed on ice for 10 min, resuspended in 20 ml of electroporation medium, and cultured at 37 °C. After 2 days, Geneticin (Life Technologies, Inc.) was added to final concentration of 3 mg ml-1. After ~2 weeks, cells were cloned by limiting dilution. Clones were screened for similar expression levels of wild-type or mutant murine CD22 by surface staining with biotinylated anti-CD22 (2D6) and flow cytometry (FACScan, Becton Dickinson, Mountain View, CA). Stable transfectants were then maintained in 1 mg ml-1 Geneticin. Wild-type and mutant DT40 cells in exponential phase were washed once in RPMI 1640 medium. DT40 cells were electroporated with 10 µg of linearized plasmid DNA containing pApuro-2-mCD22 at 290 V and 960 microfarads and cultured as described above for transfection in BJAB cells. After 2 days, puromycin (Sigma) was added at 0.5 µg ml-1. Five days later, dead cells were removed by centrifugation over IsoPrep (Robbins Scientific, Sunnyvale, CA). Cells at the interface were washed twice and cultured at 37 °C. Cells were later stained for surface expression of murine CD22 with biotinylated CD22 mAb, sorted by a FACS (FACS Vantage Turbo S.E., Becton Dickinson) for high expression of CD22, and cloned by limiting dilution. Clones were screened and selected for similar expression levels of CD22.

Biochemical Methods-- Cells in exponential phase were centrifuged and resuspended at 107 ml-1 in RP10. Cells were activated for the indicated number of minutes at 37 °C with 10 µg ml-1 of the indicated antiserum or mAb. Activation was stopped by the addition of at least 5 volumes of ice-cold phosphate-buffered saline. Cells were then washed once with phosphate-buffered saline and lysed at 30 × 106 ml-1 in Nonidet P-40 lysis buffer (50 mM Tris, pH 8.0, 5 mM EDTA, 150 mM NaCl, and 1.0% Nonidet P-40) with protease and phosphatase inhibitors (1 µg ml-1 aprotinin, 1 µg ml-1 pepstatin A, 1 µg ml-1 leupeptin, 2 mM phenylmethylsulfonyl fluoride, 10 mM NaF, 1 mM Na3VO4, 5 mM Na3PO4, and 100 µg ml-1 soybean trypsin inhibitor) for 1 h at 4 °C with constant rotation. After centrifugation at 14,000 rpm to remove nuclei, lysates were used for immunoprecipitations with the indicated mAb. Lysates with mAbs were incubated at 4 °C overnight with constant rotation. Samples were rotated for an additional 1 h at 4 °C with 50 µl of packed protein A- or protein G-Sepharose. Immunoprecipitates were washed three times with Nonidet P-40 lysis buffer, mixed with 100 µl of 1× reducing sample buffer (62.5 mM Tris, pH 6.8, 1.25% SDS, 12% glycerol, 0.05% bromphenol blue, and 5% 2-mercaptoethanol), boiled for 5 min, and frozen at -70 °C until used for SDS-PAGE. Immunoprecipitates were resolved on either a 12- or 20-cm 10% polyacrylamide gel and transferred to nylon membrane. Membranes were washed in TBST (50 mM Tris, pH 8.0, 150 mM NaCl, and 0.1% Tween 20), blocked in TBST-B (TBST with 5% bovine serum albumin) overnight, subjected to Western blotting with the indicated antiserum or mAb and the appropriate horseradish peroxidase-conjugated second antibody, and visualized by chemiluminescence (PerkinElmer Life Sciences). Densitometry was performed, and values were normalized against either Mst-1, for blots of whole cell lysates, or CD22, for blots of CD22 immunoprecipitations. In vitro kinase reactions were performed as described previously (31).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Two Carboxyl-terminal ITIM Tyrosines Are Required for Recruitment of SHP-1-- The cytoplasmic tail of CD22 contains six conserved tyrosine residues and becomes rapidly tyrosine phosphorylated following BCR engagement (11-14). Three of these tyrosines, Tyr-783, Tyr-843, and Tyr-863 (numbering is based on the unprocessed murine CD22 protein), are located within ITIM motifs as defined by the consensus motif (V/L/I)XYXX(L/I/V) (where X is any amino acid) (32). When the tyrosine residue within an ITIM motif is phosphorylated, the ITIM motif can bind molecules such as the SHP-1 protein tyrosine phosphatase and potentially play a role in activating SHP-1 (16, 18). Using phosphopeptides equivalent to the six tyrosine-containing regions in CD22, it was previously reported that phosphopeptides corresponding to the three ITIM motifs of CD22 can compete with CD22 for the binding of SHP-1, whereas the analogous nonphosphorylated peptides do not (18). These data suggested that Tyr-783, Tyr-843, and Tyr-863 were involved in the binding and activation of SHP-1 but did not clarify which of these tyrosines was required in vivo for recruitment of SHP-1 to CD22 following engagement of the BCR.

To address this question, we used the sIgM-positive human B cell line BJAB to generate a stable transfectant expressing c-Myc-tagged wild-type murine CD22 and six stable transfectants expressing mutant forms of c-Myc-tagged murine CD22 with single tyrosine to phenylalanine mutations. All seven stable lines were selected for similar expression levels of the transfected wild-type or mutant murine CD22 molecules (Fig. 1A). This system had several advantages relative to other transfection systems. Unlike non-B cell lines where CD22 has been studied, e.g. HeLa cells (33), BJAB contains the same or very similar signal transduction machinery present in normal B cells. Also, the upstream and downstream components of the signal transduction machinery are present and at unmanipulated levels. Furthermore, BCR cross-linking, a relatively physiological stimulus, was used instead of pharmacological reagents to activate the B cells. Finally, the transfected BJAB lines express endogenous human CD22, which was used as an internal positive control for recruitment of SHP-1 and was easily distinguishable from the transfected wild-type or mutant murine CD22 by specific mAbs and antisera.


View larger version (30K):
[in this window]
[in a new window]
  		Fig. 1.   The two carboxyl-terminal tyrosines in the cytoplasmic tail of CD22 are required for SHP-1 recruitment. A, stable BJAB cell line transfectants expressing wild-type or single tyrosine to phenylalanine mutants of murine CD22 were cloned by limiting dilution and screened by a FACS. Histograms show the expression levels of the wild-type or mutant murine CD22 and endogenous human CD22 (solid histogram) and the background staining by isotype-matched control mAbs (thin lines). The name of the cloned line corresponds to the form of the transfected wild-type or mutant murine CD22 cDNA. B, clones were stimulated with goat F(ab')2 anti-human IgM serum for 3 min and lysed. Human or murine CD22 was immunoprecipitated, resolved by SDS-PAGE, and transferred to nylon membrane. The nylon membranes were cut horizontally; the top portions were Western blotted with human CD22 antiserum or c-Myc mAb, and the bottom portions were blotted with anti-SHP-1 serum. Mouse IgG and rat IgG were used as controls for human CD22 and mouse CD22 immunoprecipitations, respectively. Additional control immunoprecipitations were included to show that the immunoprecipitating mAbs and blotting antisera are species-specific. Three independent experiments from two sets of clones derived independently showed similar results. wt, wild type; IP, immunoprecipitation.

Stimulation through the BCR on transfectants expressing wild-type murine CD22 led to efficient association of SHP-1 with both the transfected murine CD22 and endogenous human CD22 (Fig. 1B). This was also observed for four of the six transfectants expressing different mutant forms of murine CD22. Transfectants with single tyrosine to phenylalanine mutations at position 773, 783, 817, or 828 (Y773F, Y783F, Y817F, or Y828F, respectively) efficiently recruited SHP-1 to both the mutant murine CD22 molecules and the endogenous human CD22 in response to BCR cross-linking (Fig. 1B and data not shown). Thus, although a phosphopeptide of the "ITIM tyrosine" Tyr-783 blocked SHP-1 binding (18), phosphorylation of Tyr-783 was not required for BCR-induced SHP-1 recruitment in vivo. However, after normalizing for the amount of immunoprecipitated CD22, we found that single tyrosine to phenylalanine mutations at position 843 (Y843F) or 863 (Y863F) decreased the amount of SHP-1 recruited to CD22 by 90 and 97%, respectively, compared with the amount bound by wild-type CD22 (Fig. 1B). The endogenous human CD22 in these same cells maintained its ability to recruit SHP-1 (Fig. 1B). Thus, the upstream kinases required for phosphorylation of CD22 and recruitment of SHP-1 were not altered during the transfection and cloning process. Similar results were seen in two sets of clones generated by independent transfections. These data demonstrate that the ITIM tyrosines Tyr-843 and Tyr-863, but not Tyr-783, in murine CD22 are individually required for efficient recruitment of SHP-1 upon BCR stimulation.

CD22 Influences ERK and JNK Activation but Not p38 MAPK Activation-- Members of the MAPK family of serine/threonine protein kinases are activated after BCR ligation (26, 31, 34). Since it can recruit and activate SHP-1, CD22 has been suggested to negatively regulate BCR-induced Erk2 and JNK but not p38 MAPK activation (26). To test whether CD22 may regulate BCR-mediated activation of the MAPKs, we compared Erk1/2, JNK, and p38 MAPK phosphorylation in purified B cells from wild-type or CD22-deficient mice (22). Western blot analysis of whole B cell lysates with mAbs specific for the phosphorylated forms of the various MAPKs showed that the absence of CD22 led to only a 1.5-fold increase in Erk1/2 phosphorylation after a 1-min stimulation and 1.6-fold increase in JNK phosphorylation after a 10-min stimulation through the antigen receptor. The absence of CD22 led to a 1.3-fold decrease in the phosphorylation of p38 MAPK after a 3-min stimulation (Fig. 2A). Furthermore, in vitro kinase assays of either JNK or p38 MAPK immunoprecipitates confirmed that JNK activity was elevated only 1.6-fold, and p38 MAPK activity was decreased 1.3-fold after BCR cross-linking of cd22-/- B cells versus wild-type B cells (Fig. 2B). These results suggest that CD22 does not play a major role in regulating BCR-induced Erk2 or JNK activation as proposed (26). Poe et al. (35) did not detect JNK phosphorylation after BCR ligation of cd22-/- B cells; they did measure JNK kinase activity, and the B cells they used had detectable JNK phosphorylation prior to stimulation, which might account for differences from our results.


View larger version (37K):
[in this window]
[in a new window]
  		Fig. 2.   CD22 deficiency slightly increases Erk1/2 and JNK activation and slightly decreases p38 MAPK activation. A, B cells were purified from cd22+/+ or cd22-/- mice and activated for the indicated amounts of time (' = minutes) with either goat F(ab')2 IgG or goat F(ab')2 anti-mouse IgM serum. Postnuclear lysates were resolved by SDS-PAGE, transferred to nylon membranes, and Western blotted using phospho-MAPK-specific antisera. Blots were reprobed with anti-Mst-1 serum to determine protein loading. Data are representative of three independent experiments. B, cells were purified and stimulated as in A. Immunoprecipitations were prepared with anti-JNK serum, anti-p38 MAPK serum, or isotype control serum and subjected to an in vitro kinase reaction in the presence of exogenous substrate. Reaction mixtures were resolved by SDS-PAGE and visualized by autoradiography.

CD22 Recruits Grb2 to the Membrane following BCR Stimulation-- We have previously noted that the amino acids surrounding one of the non-ITIM tyrosines in CD22, Tyr-828, has sequence homology to two regions in the T cell- and natural killer cell-restricted molecule LAT (2). LAT is rapidly tyrosyl-phosphorylated by either Zap70 or Syk following ligation of the T cell antigen receptor and recruits the adaptor molecule Grb2 (36). Furthermore, the tyrosine residues within LAT with homology to CD22 are required for Grb2 recruitment by LAT (36, 37). Thus, we hypothesized that the cytoplasmic tail of CD22 recruits Grb2 after it is tyrosine-phosphorylated. To test this hypothesis, we immunoprecipitated human CD22 from BJAB cells after cross-linking the BCR; by Western blotting we found that Grb2 is indeed inducibly recruited to bind CD22 (Fig. 3A). A small amount of Grb2 was associated with CD22 prior to BCR ligation but is increased ~2.2-fold within 3 min following stimulation. Similarly, Grb2 was recruited to murine CD22 after purified splenic B cells were signaled through the antigen receptor (Fig. 3B). These results confirm and extend those of others (35, 38).


View larger version (29K):
[in this window]
[in a new window]
  		Fig. 3.   CD22 recruits Grb2 after BCR cross-linking. A, human CD22 was immunoprecipitated from postnuclear lysates of BJAB cells activated for the indicated number of minutes with either goat F(ab')2 IgG or goat F(ab')2 anti-human IgM serum. Mouse IgG1 mAb was used as an immunoprecipitation control. After resolving immunoprecipitates by SDS-PAGE and transferring to a nylon membrane, blots were cut horizontally. The top portion of the membrane was blotted for human CD22, and the bottom portion was blotted for Grb2. Data are representative of four independent experiments. B, B cells were purified from mice, activated with either goat F(ab')2 IgG (-) or goat F(ab')2 anti-mouse IgM (+) for 3 min, and lysed. Murine CD22 immunoprecipitates were resolved by SDS-PAGE and transferred to nylon membrane for Western blotting. Murine CD22 and Grb2 were detected as described in A except anti-murine-specific serum was used to detect murine CD22. IP, immunoprecipitation; Stim., stimulation.

Different Phosphotyrosines Recruit Grb2 and SHP-1 to CD22 following BCR Engagement-- Since CD22 appears to regulate signals in both positive and negative manners, we hypothesized that the tyrosine requirements for Grb2 and SHP-1 recruitment to CD22 were independent of each other. To test this, we analyzed our panel of stable BJAB transfectants expressing single tyrosine to phenylalanine mutants of murine CD22 for association of SHP-1 and Grb2 before and after BCR ligation. The Tyr-817 residue was not required for recruitment of either Grb2 or SHP-1 (Fig. 4). However, SHP-1 was efficiently recruited to the Y828F mutant, while Grb2 was not; thus, Tyr-828 is required for Grb2 recruitment as suggested by previous in vitro studies with phosphopeptides (35, 38). Furthermore, Grb2 recruitment remained intact in the Y843F or Y863F murine CD22 mutants, whereas SHP-1 recruitment was abolished (Fig. 4). These data suggest that CD22 contains two independent signaling domains within its cytoplasmic tail, one functioning to recruit SHP-1 and one functioning to recruit Grb2.


View larger version (61K):
[in this window]
[in a new window]
  		Fig. 4.   Different tyrosine residues in the cytoplasmic tail of CD22 are required for Grb2 and SHP-1 recruitment. The stable BJAB transfectants described in Fig. 1 were activated for 3 min as described in Fig. 3A. Murine CD22 was immunoprecipitated with rat anti-mouse CD22 mAb, and rat IgG was used for control. Immunoprecipitates were resolved by SDS-PAGE and transferred to a nylon membrane. The membrane was cut horizontally into three strips; the top portion was blotted with c-Myc mAb to detect the transfected mutant CD22, and the middle and bottom portions were blotted with antisera against SHP-1 and Grb2, respectively. Data are representative of three experiments. IP, immunoprecipitation; Stim., stimulation.

Effect of the Src Family Kinase-specific Inhibitor PP1 on Grb2 and SHP-1 Recruitment-- Based on both genetic and biochemical data, a signaling pathway involving Lyn, CD22, and SHP-1 has been established. For instance, the BCR-induced phosphorylation of CD22 is decreased in B cells from Lyn-deficient mice, and SHP-1 recruitment is abolished (39-42). This probably explains why lyn-/-, cd22-/-, and shp-1mev/mev mice have similar defects, e.g. decreased sIgM expression, increased major histocompatibility complex class II expression, and increased sensitivity to the BCR-induced increase in [Ca2+]i release (2). To test whether Grb2 recruitment to CD22 also requires Src family kinase activity, we preincubated BJAB cells in varying concentrations of the Src family kinase-specific inhibitor PP1 (43). Then we activated the cells by BCR cross-linking and analyzed the phosphorylation status of CD22 and its ability to recruit Grb2 and SHP-1 by Western blotting. Consistent with published data (39-42), we found that PP1 inhibited the induced recruitment of SHP-1 and induced tyrosine phosphorylation of CD22 in a dose-dependent manner with 61 and 37% inhibition at 10 µM PP1, respectively (Fig. 5). Further analysis showed that 50% inhibition occurred at 5 µM for SHP-1 recruitment and 18 µM for induced tyrosine phosphorylation. Interestingly, Grb2 recruitment showed only 0 and 2% inhibition at 2 and 10 µM PP1 (Fig. 5). Densitometric analysis revealed that at 50 µM PP1, Grb2 binding was decreased 23% versus the amount seen without PP1, demonstrating that Grb2 binding can be blocked in this system. This effect at 50 µM may be due to decreased specificity of the Src family kinase-specific inhibitor at high doses. Nonetheless, these data suggest that SHP-1 and Grb2 recruitment to CD22 are differentially regulated by upstream kinases and further support the hypothesis that CD22 regulates at least two independent signaling pathways initiated by the BCR.


View larger version (82K):
[in this window]
[in a new window]
  		Fig. 5.   Grb2 recruitment to CD22 is not inhibited by the Src family kinase-specific inhibitor PP1. BJAB cells were incubated for 30 min with the indicated concentrations of PP1 and activated with either goat F(ab')2 anti-human IgM (+) or goat F(ab')2 IgG (-) for 3 min. Me2SO was added so the concentration of vehicle was identical in all samples. Lysates and immunoprecipitates were prepared as described in Fig. 3b. Samples were split, and replicate gels were run. Blots were probed with anti-human CD22, anti-SHP-1, and anti-Grb2 sera and phosphotyrosine (P-Y) mAb. Data are representative of three experiments. IP, immunoprecipitation; Stim., stimulation.

Both Lyn and Syk Contribute to the Constitutive and Induced Tyrosine Phosphorylation of CD22-- Since BCR-induced tyrosine phosphorylation of CD22 in B cells from Lyn-deficient mice is reduced but not completely absent (39-42), we hypothesized that another PTK can phosphorylate the cytoplasmic tail of CD22. Furthermore, since the Syk family PTK Zap70 phosphorylates LAT (36) and Syk physically associates with CD22 (16), we tested whether Syk could affect CD22 tyrosine phosphorylation. To address this question, we used the chicken B cell line DT40 and three mutant lines derived from DT40 that are deficient in expression of specific tyrosine kinases. Stable transfectants expressing c-Myc-tagged murine CD22 were isolated using wild-type chicken DT40 B cells, Lyn-deficient (Lyn-), Syk-deficient (Syk-), and Lyn/Syk double-deficient (Lyn-Syk-) mutant cells (28, 29). Transfectants were selected for similar expression of c-Myc-tagged murine CD22 (Fig. 6A). CD22 was constitutively phosphorylated in wild-type DT40 cells, and phosphorylation increased significantly after BCR cross-linking (Fig. 6B). BCR-induced phosphorylation of CD22 was decreased 70% in Lyn- and 25% in Syk- DT40 cells relative to the induced phosphorylation in wild-type cells, showing that both PTKs are required for maximal phosphorylation of CD22. In the absence of both Lyn and Syk, tyrosine phosphorylation of CD22 was not observed even when the blot was intentionally overexposed (Fig. 6B). This demonstrates that together Lyn and Syk are responsible for all of the constitutive and induced tyrosine phosphorylation of CD22. These data also suggest that the small amount of BCR-induced tyrosine phosphorylation of CD22 observed in lyn-/- B cells (Fig. 6B and Refs. 39-42) is indeed Syk-dependent.


View larger version (28K):
[in this window]
[in a new window]
  		Fig. 6.   Tyrosine phosphorylation of CD22 is dependent on both Lyn and Syk. A, wild-type (WT), Lyn-deficient (Lyn-), Syk-deficient (Syk-) and Lyn/Syk double-deficient (Lyn-Syk-) chicken DT40 cells were transfected with c-Myc-tagged murine CD22. Stable transfectants were sorted by a FACS for similar surface expression and cloned by limiting dilution. Cells were stained with murine CD22 mAb (solid histogram) or isotype control (thin lines). B, stable transfectants were stimulated for 3 min with chicken IgM mAb (+) or mouse IgM (-) and lysed. Anti-CD22 mAb or control rat IgG was used for immunoprecipitation. Samples were split, and replicate gels were run and transferred to nylon membranes. Blots were probed with either phosphotyrosine (P-Y) or c-Myc mAb. The anti-phosphotyrosine blot was intentionally overexposed to show the complete lack of CD22 tyrosine phosphorylation in Lyn-Syk- cells. IP, immunoprecipitation; Stim., stimulation; Wt, wild type.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Many factors determine the fate of a B cell upon encounter with antigen (1), including the participation or lack of participation of coreceptors such as CD22 (2). Previous evidence suggests that CD22 can negatively regulate signals initiated by the BCR by recruiting and activating the protein tyrosine phosphatase SHP-1 (18, 26). The tyrosine kinase Lyn is required for this recruitment, thereby defining a signaling pathway in which Lyn directly or indirectly phosphorylates CD22 and promotes SHP-1 recruitment (39-42). Mice homozygous for mutations at each of these three loci have similar phenotypes with respect to sIgM down-regulation, major histocompatibility complex class II up-regulation, and increased sensitivity to BCR-mediated increase in [Ca2+]i (2). Furthermore, Lyn, CD22, and SHP-1 regulate tolerance induction in a polygenic manner (40). These data suggest that a Lyn/CD22/SHP-1 "inhibitory pathway" regulates some B cell responses (10). However, data from this study suggest that CD22 may also regulate other signaling pathways.

We have defined which of the six tyrosines in the cytoplasmic tail of CD22 are required for SHP-1 recruitment following BCR ligation. Three of the six tyrosine residues within the cytoplasmic tail of CD22 correspond to classic ITIM motifs (18, 32), but only two of these ITIM tyrosines, Tyr-843 and Tyr-863, are required for efficient SHP-1 recruitment. Although a phosphopeptide containing Tyr-783, like Tyr-843- and Tyr-863-containing phosphopeptides, could compete for SHP-1 binding to CD22 and increase the phosphatase activity in vitro (18), Tyr-783 was not required for BCR-induced recruitment of SHP-1 in vivo (Fig. 1B). Recent studies suggest that CD22 is also a substrate for SHP-1 phosphatase activity and that these three ITIM tyrosines may be the sites of dephosphorylation (33, 44). By overexpressing substrate-trapping and catalytically inactive SHP-1 with a chimeric CD22 molecule in HeLa cells, Blasioli et al. (33) have suggested that phosphorylation of Tyr-783 may stabilize the binding of SHP-1 to CD22. Whether or not Tyr-783 is normally tyrosine-phosphorylated and -dephosphorylated in vivo after BCR ligation remains to be determined. Since a small amount of SHP-1 is recruited to CD22 when Tyr-843 is mutated to phenylalanine, phosphorylated Tyr-843 may also function to stabilize the binding of SHP-1 to CD22. Our results suggest that Tyr-773, Tyr-783, and Tyr-817 are not essential for either SHP-1 or Grb2 recruitment.

Interestingly, some defects observed in cd22-/- mice are not observed in lyn-/- or shp-1mev/mev mice (2). For instance, the antibody responses to thymus-independent type II antigens are relatively normal in lyn-/- mice (45, 46) but decreased in cd22-/- mice (22, 25). Even more telling is the observation that when stimulated through the antigen receptor in vitro, cd22-/- B cells proliferate less well than wild-type B cells (22, 24), whereas B cells purified from lyn-/- or shp-1mev/mev mice are hyper-responsive to similar stimuli (47-49). These data suggest that CD22 may regulate BCR-mediated signals in a Lyn- and SHP-1-independent manner. Other studies also have suggested that CD22 may signal independently of Lyn and SHP-1. Chan et al. (39) have found that cross-linking CD22 leads to low level Erk2 and JNK activation in the absence of Lyn.

We have found that a region in CD22 is functionally similar to two regions in LAT (2). This region, containing Tyr-828, recruits the adaptor molecule Grb2 (Fig. 4). In contrast to SHP-1, Grb2 recruitment to CD22 is not inhibited by 2 and 10 µM PP1 (Fig. 5), doses that specifically inhibit Src family PTKs (43). Grb2 recruitment is slightly inhibited at 50 µM PP1, which may be due to decreased specificity of the inhibitor. These data suggest that Grb2 recruitment may not require a Src family kinase. Alternatively, Lyn and a non-Src family PTK together may influence the localization and/or activity of each other upstream of CD22 phosphorylation. Nevertheless, we cannot formally rule out a role for Lyn or other Src family PTKs in the recruitment of Grb2 to CD22. However, our data are most consistent with the model that SHP-1 and Grb2 recruitment to CD22 are differentially regulated by upstream PTKs. Furthermore, since Syk and Zap70 phosphorylate the analogous regions in LAT leading to Grb2 recruitment in T cells (36, 37) and Grb2 binds to CD22 in a phosphorylation-dependent manner (35, 38), Syk is a likely candidate for phosphorylating Tyr-828 in CD22 and facilitating the binding of Grb2. Moreover, Syk associates with CD22 (16) and is required for maximal phosphorylation of CD22 (Fig. 6B). However, preincubation of BJAB cells with the Syk-selective inhibitor piceatannol (50) over a range of doses did not inhibit the induced recruitment of Grb2 to CD22 (data not shown). Furthermore, analysis of the ability of CD22 to associate with endogenous SHP-1 and Grb2 in BCR-activated wild-type and mutant chicken DT40 lines proved inconclusive due to the lack of specific reagents that reliably detect chicken signaling molecules (data not shown). Therefore, we have not definitively implicated Syk in the phosphorylation of Tyr-828 and Grb2 recruitment. Further studies will be required to clarify the role of Syk in recruiting Grb2 to CD22.

CD22 apparently contains at least two signaling domains that regulate BCR-mediated signaling pathways. These tyrosine-based domains are defined by the molecules they recruit to the membrane following BCR ligation. One domain, containing Tyr-843 and Tyr-863, is most likely phosphorylated by Lyn and is required for efficient SHP-1 recruitment. Another domain, containing Tyr-828, is required for Grb2 recruitment and may promote a proliferative pathway. This model explains the various defects observed in cd22-/- mice compared with lyn-/- and shp-1mev/mev mice; it also predicts that these two signaling pathways regulate different aspects of B cell responses. The Lyn/CD22/SHP-1 pathway almost certainly regulates sIgM expression, major histocompatibility complex class II expression, and probably the BCR-induced increase in [Ca2+]i (2). The proposed CD22/Grb2 pathway may regulate proliferative responses to anti-IgM and antibody responses to thymus-independent type II antigens, perhaps with Shc and Src homology 2-containing inositol 5'-phosphatase (35). In the absence of CD22, we propose that both signaling pathways are disrupted, whereas in the absence of either Lyn or SHP-1 only one of the two CD22-regulated pathways is completely disrupted. We are currently testing this hypothesis by creating mice that express mutant forms of CD22 with single tyrosine to phenylalanine substitutions within each signaling domain. We predict that each of these lines of mice will show a subset of the defects observed in CD22-deficient mice.

Pezzutto et al. (51, 52) have shown that preincubation of human B cells with CD22 mAb lowered the threshold for BCR-induced proliferation and increase in [Ca2+]i signaling through the BCR. This provided initial functional data on the role of CD22 in regulating the BCR. These data were interpreted as suggesting that cross-linking CD22 provided an incomplete or subthreshold signal that synergized with the BCR. Since then, similar data showing that ligating CD22 can amplify BCR-induced proliferation were interpreted in a different manner; Doody et al. (18, 26) have suggested that CD22 is a negative regulator and that preincubation with mAb "sequesters" CD22 away from the BCR, thereby relieving it of the inhibitory affects of CD22-associated SHP-1. Determining which of these interpretations most accurately describes the function of CD22 has been difficult in part because preincubating cells with mAbs that cross-link CD22 could either induce a signal (16, 53, 54) and/or sequester CD22 away from the BCR complex (18, 26). Our model offers an explanation for these and other published data, namely that CD22 has dual functions. Furthermore, this model may offer a biochemical explanation of the paradoxical phenotype of the CD22-deficient mice (22, 24, 25). As with so many other receptors regulating B cell fate, such as CD40, CD95, and the BCR itself (2), CD22 too has more than one potential function.

    ACKNOWLEDGEMENTS

We thank Dr. Z. Joe Zhao (Vanderbilt University, Nashville, TN) for providing the SHP-1 antiserum (16), Dr. Mary-Ann Campbell (La Jolla Pharmaceutical Company, San Diego, CA) for providing the murine CD22 blotting antisera (17), Dr. Jonathan Chernoff (Fox Chase Cancer Center, Philadelphia, PA) for providing the Mst-1 antiserum (55), and Dr. Jeremy Saklatvala (Babraham Institute, Cambridge, UK) for providing the p38 MAPK antiserum (SAK-7) (56). We also thank Dr. Tomohiro Kurosaki (Kansai Medical University, Osaka, Japan) for providing the wild-type and mutant DT40 cells, the pApuro-2 vector, and the M4 hybridoma line (28, 29). Drs. Che-Leung Law, Theodore J. Yun, and Jonathan Graves offered invaluable advice throughout this study. Finally, we thank Marj Domenowske for assistance in preparing figures.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants AI44250 and RR00166 (to E. A. C.) and a Howard Hughes Medical Institute predoctoral fellowship (to K. L. O.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Regional Primate Research Center, Box 357330, University of Washington, Seattle, WA 98195. Tel.: 206-543-2619; Fax: 206-685-0305; E-mail: kotipoby@u.washington.edu.

Published, JBC Papers in Press, September 10, 2001, DOI 10.1074/jbc.M105446200

    ABBREVIATIONS

The abbreviations used are: BCR, B cell antigen receptor; ITIM, immunoreceptor tyrosine-based inhibitory motif; PTK, protein tyrosine kinase; sIgM, surface IgM; MAPK, mitogen-activated protein kinase; Lyn-, Lyn-deficient; Syk-, Syk-deficient; Lyn-Syk-, Lyn and Syk double-deficient; PAGE, polyacrylamide gel electrophoresis; EBV, Epstein-Barr virus; PCR, polymerase chain reaction; mAb, monoclonal antibody; JNK, c-Jun NH2-terminal kinase; ERK, extracellular signal-regulated kinase; HA, hemagglutinin; FACS, fluorescence-activated cell sorter; LAT, linker for activation of T cells; PP1, 4-amino-5- (4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Goodnow, C. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2264-2271[Abstract/Free Full Text]
2. Craxton, A., Otipoby, K. L., Jiang, A., and Clark, E. A. (1999) Adv. Immunol. 73, 79-152[Medline] [Order article via Infotrieve]
3. Tedder, T. F., Tuscano, J., Sato, S., and Kehrl, J. H. (1997) Annu. Rev. Immunol. 15, 481-504[CrossRef][Medline] [Order article via Infotrieve]
4. Carroll, M. C. (2000) Adv. Immunol. 74, 61-88[Medline] [Order article via Infotrieve]
5. Bolland, S., and Ravetch, J. V. (1999) Adv. Immunol. 72, 149-177[Medline] [Order article via Infotrieve]
6. Pan, C., Baumgarth, N., and Parnes, J. R. (1999) Immunity 11, 495-506[CrossRef][Medline] [Order article via Infotrieve]
7. Kurosaki, T. (1999) Annu. Rev. Immunol. 17, 555-592[CrossRef][Medline] [Order article via Infotrieve]
8. DeFranco, A. L. (1997) Curr. Opin. Immunol. 9, 296-308[CrossRef][Medline] [Order article via Infotrieve]
9. Law, C. L., Sidorenko, S. P., and Clark, E. A. (1994) Immunol. Today 15, 442-449[CrossRef][Medline] [Order article via Infotrieve]
10. Cyster, J. G., and Goodnow, C. C. (1997) Immunity 6, 509-517[CrossRef][Medline] [Order article via Infotrieve]
11. Schulte, R. J., Campbell, M. A., Fischer, W. H., and Sefton, B. M. (1992) Science 258, 1001-1004[Abstract/Free Full Text]
12. Stamenkovic, I., and Seed, B. (1990) Nature 345, 74-77[CrossRef][Medline] [Order article via Infotrieve]
13. Wilson, G. L., Fox, C. H., Fauci, A. S., and Kehrl, J. H. (1991) J. Exp. Med. 173, 137-146[Abstract/Free Full Text]
14. Torres, R. M., Law, C. L., Santos-Argumedo, L., Kirkham, P. A., Grabstein, K., Parkhouse, R. M., and Clark, E. A. (1992) J. Immunol. 149, 2641-2649[Abstract]
15. Tuscano, J. M., Engel, P., Tedder, T. F., Agarwal, A., and Kehrl, J. H. (1996) Eur. J. Immunol. 26, 1246-1252[Medline] [Order article via Infotrieve]
16. Law, C. L., Sidorenko, S. P., Chandran, K. A., Zhao, Z., Shen, S. H., Fischer, E. H., and Clark, E. A. (1996) J. Exp. Med. 183, 547-560[Abstract/Free Full Text]
17. Campbell, M. A., and Klinman, N. R. (1995) Eur. J. Immunol. 25, 1573-1579[Medline] [Order article via Infotrieve]
18. Doody, G. M., Justement, L. B., Delibrias, C. C., Matthews, R. J., Lin, J., Thomas, M. L., and Fearon, D. T. (1995) Science 269, 242-244[Abstract/Free Full Text]
19. Lankester, A. C., van Schijndel, G. M., and van Lier, R. A. (1995) J. Biol. Chem. 270, 20305-20308[Abstract/Free Full Text]
20. Leprince, C., Draves, K. E., Geahlen, R. L., Ledbetter, J. A., and Clark, E. A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3236-3240[Abstract/Free Full Text]
21. Peaker, C. J., and Neuberger, M. S. (1993) Eur. J. Immunol. 23, 1358-1363[Medline] [Order article via Infotrieve]
22. Otipoby, K. L., Andersson, K. B., Draves, K. E., Klaus, S. J., Farr, A. G., Kerner, J. D., Perlmutter, R. M., Law, C. L., and Clark, E. A. (1996) Nature 384, 634-637[CrossRef][Medline] [Order article via Infotrieve]
23. O'Keefe, T. L., Williams, G. T., Davies, S. L., and Neuberger, M. S. (1996) Science 274, 798-801[Abstract/Free Full Text]
24. Sato, S., Miller, A. S., Inaoki, M., Bock, C. B., Jansen, P. J., Tang, M. L., and Tedder, T. F. (1996) Immunity 5, 551-562[CrossRef][Medline] [Order article via Infotrieve]
25. Nitschke, L., Carsetti, R., Ocker, B., Kohler, G., and Lamers, M. C. (1997) Curr. Biol. 7, 133-143[CrossRef][Medline] [Order article via Infotrieve]
26. Tooze, R. M., Doody, G. M., and Fearon, D. T. (1997) Immunity 7, 59-67[CrossRef][Medline] [Order article via Infotrieve]
27. Law, C. L., Torres, R. M., Sundberg, H. A., Parkhouse, R. M., Brannan, C. I., Copeland, N. G., Jenkins, N. A., and Clark, E. A. (1993) J. Immunol. 151, 175-187[Abstract]
28. Takata, M., Sabe, H., Hata, A., Inazu, T., Homma, Y., Nukada, T., Yamamura, H., and Kurosaki, T. (1994) EMBO J. 13, 1341-1349[Medline] [Order article via Infotrieve]
29. Qin, S., Inazu, T., Takata, M., Kurosaki, T., Homma, Y., and Yamamura, H. (1996) Eur. J. Biochem. 236, 443-449[Medline] [Order article via Infotrieve]
30. Hardy, R. R. (1986) in Handbook of Experimental Immunology (Weir, D. M. , Herzenberg, L. A. , Blackwell, C. , and Herzenberg, L. A., eds), 4th Ed., Vol. 1 , pp. 1-12, Blackwell Scientific Publications, Oxford
31. Jiang, A., Craxton, A., Kurosaki, T., and Clark, E. A. (1998) J. Exp. Med. 188, 1297-1306[Abstract/Free Full Text]
32. Thomas, M. L. (1995) J. Exp. Med. 181, 1953-1956[Free Full Text]
33. Blasioli, J., Paust, S., and Thomas, M. L. (1999) J. Biol. Chem. 274, 2303-2307[Abstract/Free Full Text]
34. Hashimoto, A., Okada, H., Jiang, A., Kurosaki, M., Greenberg, S., Clark, E. A., and Kurosaki, T. (1998) J. Exp. Med. 188, 1287-1295[Abstract/Free Full Text]
35. Poe, J. C., Fujimoto, M., Jansen, P. J., Miller, A. S., and Tedder, T. F. (2000) J. Biol. Chem. 275, 17420-17427[Abstract/Free Full Text]
36. Zhang, W., Sloan-Lancaster, J., Kitchen, J., Trible, R. P., and Samelson, L. E. (1998) Cell 92, 83-92[CrossRef][Medline] [Order article via Infotrieve]
37. Zhang, W., Trible, R. P., Zhu, M., Liu, S. K., McGlade, C. J., and Samelson, L. E. (2000) J. Biol. Chem. 275, 23355-23361[Abstract/Free Full Text]
38. Yohannan, J., Wienands, J., Coggeshall, K. M., and Justement, L. B. (1999) J. Biol. Chem. 274, 18769-18776[Abstract/Free Full Text]
39. Chan, V. W., Lowell, C. A., and DeFranco, A. L. (1998) Curr. Biol. 8, 545-553[CrossRef][Medline] [Order article via Infotrieve]
40. Cornall, R. J., Cyster, J. G., Hibbs, M. L., Dunn, A. R., Otipoby, K. L., Clark, E. A., and Goodnow, C. C. (1998) Immunity 8, 497-508[CrossRef][Medline] [Order article via Infotrieve]
41. Smith, K. G. C., Tarlinton, D. M., Doody, G. M., Hibbs, M. L., and Fearon, D. T. (1998) J. Exp. Med. 187, 807-811[Abstract/Free Full Text]
42. Nishizumi, H., Horikawa, K., Mlinaric-Rascan, I., and Yamamoto, T. (1998) J. Exp. Med. 187, 1343-1348[Abstract/Free Full Text]
43. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., and Connelly, P. A. (1996) J. Biol. Chem. 271, 695-701[Abstract/Free Full Text]
44. Yang, J., Cheng, Z., Niu, T., Liang, X., Zhao, Z. J., and Zhou, G. W. (2000) J. Biol. Chem. 275, 4066-4071[Abstract/Free Full Text]
45. Nishizumi, H., Taniuchi, I., Yamanashi, Y., Kitamura, D., Ilic, D., Mori, S., Watanabe, T., and Yamamoto, T. (1995) Immunity 3, 549-560[CrossRef][Medline] [Order article via Infotrieve]
46. Hibbs, M. L., Tarlinton, D. M., Armes, J., Grail, D., Hodgson, G., Maglitto, R., Stacker, S. A., and Dunn, A. R. (1995) Cell 83, 301-311[CrossRef][Medline] [Order article via Infotrieve]
47. Wang, J., Koizumi, T., and Watanabe, T. (1996) J. Exp. Med. 184, 831-838[Abstract/Free Full Text]
48. Chan, V. W., Meng, F., Soriano, P., DeFranco, A. L., and Lowell, C. A. (1997) Immunity 7, 69-81[CrossRef][Medline] [Order article via Infotrieve]
49. Pani, G., Kozlowski, M., Cambier, J. C., Mills, G. B., and Siminovitch, K. A. (1995) J. Exp. Med. 181, 2077-2084[Abstract/Free Full Text]
50. Oliver, J. M., Burg, D. L., Wilson, B. S., McLaughlin, J. L., and Geahlen, R. L. (1994) J. Biol. Chem. 269, 29697-29703[Abstract/Free Full Text]
51. Pezzutto, A., Dorken, B., Moldenhauer, G., and Clark, E. A. (1987) J. Immunol. 138, 98-103[Abstract]
52. Pezzutto, A., Rabinovitch, P. S., Dorken, B., Moldenhauer, G., and Clark, E. A. (1988) J. Immunol. 140, 1791-1795[Abstract/Free Full Text]
53. Tuscano, J., Engel, P., Tedder, T. F., and Kehrl, J. H. (1996) Blood 87, 4723-4730[Abstract/Free Full Text]
54. Tuscano, J. M., Riva, A., Toscano, S. N., Tedder, T. F., and Kehrl, J. H. (1999) Blood 94, 1382-1392[Abstract/Free Full Text]
55. Graves, J. D., Gotoh, Y., Draves, K. E., Ambrose, D., Han, D. K., Wright, M., Chernoff, J., Clark, E. A., and Krebs, E. G. (1998) EMBO J. 17, 2224-2234[CrossRef][Medline] [Order article via Infotrieve]
56. Graves, J. D., Draves, K. E., Craxton, A., Saklatvala, J., Krebs, E. G., and Clark, E. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13814-13818[Abstract/Free Full Text]

Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 JEMHome page
S. J. Kim, M. Caton, C. Wang, M. Khalil, Z.-J. Zhou, J. Hardin, and B. Diamond
Increased IL-12 inhibits B cells' differentiation to germinal center cells and promotes differentiation to short-lived plasmablasts
J. Exp. Med., September 29, 2008; 205(10): 2437 - 2448.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
A. Rinna and H. J. Forman
SHP-1 Inhibition by 4-Hydroxynonenal Activates Jun N-Terminal Kinase and Glutamate Cysteine Ligase
Am. J. Respir. Cell Mol. Biol., July 1, 2008; 39(1): 97 - 104.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Zhu, M. Sato, T. Yanagisawa, M. Fujimoto, and T. Tsubata
Novel Binding Site for Src Homology 2-containing Protein-tyrosine Phosphatase-1 in CD22 Activated by B Lymphocyte Stimulation with Antigen
J. Biol. Chem., January 18, 2008; 283(3): 1653 - 1659.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
Y. Liu, M. J. Kruhlak, J.-J. Hao, and S. Shaw
Rapid T cell receptor-mediated SHP-1 S591 phosphorylation regulates SHP-1 cellular localization and phosphatase activity
J. Leukoc. Biol., September 1, 2007; 82(3): 742 - 751.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
K. Horikawa, S. W. Martin, S. L. Pogue, K. Silver, K. Peng, K. Takatsu, and C. C. Goodnow
Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors
J. Exp. Med., April 16, 2007; 204(4): 759 - 769.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
P. K. Grewal, M. Boton, K. Ramirez, B. E. Collins, A. Saito, R. S. Green, K. Ohtsubo, D. Chui, and J. D. Marth
ST6Gal-I Restrains CD22-Dependent Antigen Receptor Endocytosis and Shp-1 Recruitment in Normal and Pathogenic Immune Signaling.
Mol. Cell. Biol., July 1, 2006; 26(13): 4970 - 4981.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Chemnitz, A. R. Lanfranco, I. Braunstein, and J. L. Riley
B and T Lymphocyte Attenuator-Mediated Signal Transduction Provides a Potent Inhibitory Signal to Primary Human CD4 T Cells That Can Be Initiated by Multiple Phosphotyrosine Motifs.
J. Immunol., June 1, 2006; 176(11): 6603 - 6614.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Fujimoto, Y. Kuwano, R. Watanabe, N. Asashima, H. Nakashima, S. Yoshitake, H. Okochi, K. Tamaki, J. C. Poe, T. F. Tedder, et al.
B Cell Antigen Receptor and CD40 Differentially Regulate CD22 Tyrosine Phosphorylation
J. Immunol., January 15, 2006; 176(2): 873 - 879.
[Abstract] [Full Text] [PDF]

Home page
 GlycobiologyHome page
A. Varki and T. Angata
Siglecs--the major subfamily of I-type lectins
Glycobiology, January 1, 2006; 16(1): 1R - 27R.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
N. Asano, M. Fujimoto, N. Yazawa, S. Shirasawa, M. Hasegawa, H. Okochi, K. Tamaki, T. F. Tedder, and S. Sato
B Lymphocyte Signaling Established by the CD19/CD22 Loop Regulates Autoimmunity in the Tight-Skin Mouse
Am. J. Pathol., August 1, 2004; 165(2): 641 - 650.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. C. Poe, K. M. Haas, J. Uchida, Y. Lee, M. Fujimoto, and T. F. Tedder
Severely Impaired B Lymphocyte Proliferation, Survival, and Induction of the c-Myc:Cullin 1 Ubiquitin Ligase Pathway Resulting from CD22 Deficiency on the C57BL/6 Genetic Background
J. Immunol., February 15, 2004; 172(4): 2100 - 2110.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
A. Verbrugge, T. d. Ruiter, H. Clevers, and L. Meyaard
Differential contribution of the immunoreceptor tyrosine-based inhibitory motifs of human leukocyte-associated Ig-like receptor-1 to inhibitory function and phosphatase recruitment
Int. Immunol., November 1, 2003; 15(11): 1349 - 1358.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
K. Silver and R. J. Cornall
Isotype Control of B Cell Signaling
Sci. Signal., May 27, 2003; 2003(184): pe21 - pe21.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. John, B. R. Herrin, C. Raman, Y.-n. Wang, K. R. Bobbitt, B. A. Brody, and L. B. Justement
The B Cell Coreceptor CD22 Associates with AP50, a Clathrin-Coated Pit Adapter Protein, Via Tyrosine-Dependent Interaction
J. Immunol., April 1, 2003; 170(7): 3534 - 3543.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Z. Zhang, K. Shen, W. Lu, and P. A. Cole
The Role of C-terminal Tyrosine Phosphorylation in the Regulation of SHP-1 Explored via Expressed Protein Ligation
J. Biol. Chem., February 7, 2003; 278(7): 4668 - 4674.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. M. Yankee, S. A. Solow, K. D. Draves, and E. A. Clark
Expression of the Grb2-Related Protein of the Lymphoid System in B Cell Subsets Enhances B Cell Antigen Receptor Signaling Through Mitogen-Activated Protein Kinase Pathways
J. Immunol., January 1, 2003; 170(1): 349 - 355.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
C. H. Nielsen and R. G. Q. Leslie
Complement's participation in acquired immunity
J. Leukoc. Biol., August 1, 2002; 72(2): 249 - 261.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
L. Jin, P. A. McLean, B. G. Neel, and H. H. Wortis
Sialic Acid Binding Domains of CD22 Are Required For Negative Regulation of B Cell Receptor Signaling
J. Exp. Med., May 6, 2002; 195(9): 1199 - 1205.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/47/44315    most recent
M105446200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Otipoby, K. L.
Right arrow Articles by Clark, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Otipoby, K. L.
Right arrow Articles by Clark, E. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement